Editas medicine Pipeline 2017 HSV

[ninguno24]

Hello guys I bring a link of editas medicine that contain their projects in a timeline. 

http://www.editasmedicine.com/our-programs

As you can see they have a program for hsv 1, I know that it's for keratitis but it's the same pathogen hsv 1, I think that they are going to accept people with hsv 1 oral or keratitis is the same.

what do you think? it will be for 2017? supposing that lca10 and hsv 1 have the same delivery mode comparing with other that are different.

post your comment!

[YammyTea]

Very hopeful! A step in the right direction.

 

[for ev4r]

 

Someone should try to call the contact phones and ask them directly

[hopeful Rylee]

I saw this link and was encouraged. Hope its not another false hope...

 

1 hour ago, for ev4r said:

 

Someone should try to call the contact phones and ask them directly

Was there a phone number? Or even an email. Its been a while since I saw it.

[hopeful Rylee]

3 hours ago, ninguno24 said:

Hello guys I bring a link of editas medicine that contain their projects in a timeline. 

http://www.editasmedicine.com/our-programs

As you can see they have a program for hsv 1, I know that it's for keratitis but it's the same pathogen hsv 1, I think that they are going to accept people with hsv 1 oral or keratitis is the same.

what do you think? it will be for 2017? supposing that lca10 and hsv 1 have the same delivery mode comparing with other that are different.

post your comment!

Hopefully this will truly happen in 2017. I have hsv2,but any progress is a step to pave the way for us all.

[ninguno24]

yeah there is a phone number it's 617 401 9000 I have not called because my english it's not perfect but I will appreciate if someone call and tell us thank you!

[Evaluate]

Thanks for sharing the link.  Editas has been quite adamant that they want to have their first clinical trial (testing in humans) to happen in 2017.  My understanding is that their first testing of CRISPR/Cas will be with individuals who have LCA, a type of eye disorder that is genetic in nature.  It's possible that they will have the Herpes Keratitis HSV-1 trial either at the same time or after but I haven't found a timeline anywhere for that project specifically.  If I am interpreting the site correctly, it says their first product candidate in clinic in 2017, so if that page is any indication of the order that they want to projects to move forward, H Keratitis is second.

Regardless of what project(s) they choose to go ahead with in 2017, it will be really exciting to see what comes of the gene editing technology being tested in humans!  I'm not aware of any FDA approved gene editing to date, so Editas could be lead the way of the future.

Edited December 28, 2016 by Evaluate

[hopeful Rylee]

I called today and was forwarded to a message. I left a voicemail.

[Tiberius]

same pathogen but isn't oral easy to locate and hsv-1 in the spine is near impossible?  Keep us updated this could be a massive breakthrough.  

[ninguno24]

Guys  I sent an email to Editas Medicine and Dr.Cullen, until now I received an answers from Cullen I made two questions about it here are his answers 

Questions

 

1-) Is Hsv 1 included for clinical trials in 2017?

I doubt it as we need to do more animal tests first

 

2-) is that research only will be for hsv 1 keratitis or it will be to oral hsv 1 too?

Only HSV keratitis initially but, if successful, we will rapidly proceed to other indications

 

that answers not were what I was waiting for, first they need more animal test? really how many years they are going to spend in animal trials? 

 

in second hand guys be realistic if you cure keratitis you cure oral too, because you have to reach latent virus and kill them not matter is the way is from lips or eyes, keratitis can't be cure if you don't kill latent hsv 1 and if you do it there is no way that you get cold sore because this is the pathogen that cause both disease oral and keratitis, is the same if you apply that in the lips there is no way that you get keratitis because you get cure for hsv 1.

 

well I'm waiting for Editas medicine answer, and I sent an email for Excision Therapeutics and Dr Kamel Khalili they have a clinical trials for 2018. 

 

Guys it's necessarily that we call them for getting new info, at least it's sure that on 2018 a clinical trials is going to start  

 

Here I'm going to provide you phone number of Excision, Editas and Kamel lab.

 

Kamel Lab 215-707-5192

Excision 646 799 0781

Editas medicine 617 401 9000 (maybe they give us some different info compared with Cullen)

Please call guys 

Thanks you!!

 

 

 

[hopeful Rylee]

Who is starting trials the soonest? Human trials... Not animals

[Evaluate]

42 minutes ago, hopeful Rylee said:

Who is starting trials the soonest? Human trials... Not animals

What do you mean?  Who is starting gene editing trials first or gene editing trials for HSV specifically?

Edited January 3, 2017 by Evaluate

[ninguno24]

2 hours ago, hopeful Rylee said:

Who is starting trials the soonest? Human trials... Not animals

Well I was supposing that Editas/Cullen would begin clinical trials for hsv 1 on 2017 but as you can see Cullen says I doubt it as need we need to do more animals test first.

But for sure Excision Therapeutics has a clinical trials for 2018 as you can see in their page http://www.excisionbio.com/pipeline  they are working with Dr Kamel Khalili, like Cullen is working with Editas Medicine.

I guest that they are in a race to get a cure as soon as they can. I don't know if they can advance clinical trials but they are working hard to develop a product that they can sell for cure a disease that many as 90% of people have, just imagine money everywhere for them and that is the principal reason to develop a cure and of course second for health people.

Not mentioned that University of Utrecht led by  Dr. Lebbink  is still working  to find a cure and as you can see their main objective if for herpes simplex virus look official page http://blogs.plos.org/speakingofmedicine/2016/08/04/crispr-puts-up-a-fight-against-persistent-herpesviruses-a-short-animation/

Edited January 3, 2017 by ninguno24
a word

[dont quit!17]

On 12/30/2016 at 2:05 PM, ninguno24 said:

Guys  I sent an email to Editas Medicine and Dr.Cullen, until now I received an answers from Cullen I made two questions about it here are his answers 

Questions

 

1-) Is Hsv 1 included for clinical trials in 2017?

I doubt it as we need to do more animal tests first

 

2-) is that research only will be for hsv 1 keratitis or it will be to oral hsv 1 too?

Only HSV keratitis initially but, if successful, we will rapidly proceed to other indications

 

that answers not were what I was waiting for, first they need more animal test? really how many years they are going to spend in animal trials? 

 

in second hand guys be realistic if you cure keratitis you cure oral too, because you have to reach latent virus and kill them not matter is the way is from lips or eyes, keratitis can't be cure if you don't kill latent hsv 1 and if you do it there is no way that you get cold sore because this is the pathogen that cause both disease oral and keratitis, is the same if you apply that in the lips there is no way that you get keratitis because you get cure for hsv 1.

 

well I'm waiting for Editas medicine answer, and I sent an email for Excision Therapeutics and Dr Kamel Khalili they have a clinical trials for 2018. 

 

Guys it's necessarily that we call them for getting new info, at least it's sure that on 2018 a clinical trials is going to start  

 

Here I'm going to provide you phone number of Excision, Editas and Kamel lab.

 

Kamel Lab 215-707-5192

Excision 646 799 0781

Editas medicine 617 401 9000 (maybe they give us some different info compared with Cullen)

Please call guys 

Thanks you!!

 

 

 

I have a feeling that Cullen and Bloom are having troubles getting anything done worth mentioning. They have a bunch of funding so they are almost expected to come out with the goods. Hopefully they are starting to figure this out. I'm not too optimistic with the whole AAV thing. 

Edited January 3, 2017 by dont quit!17

[Evaluate]

1 minute ago, dont quit!17 said:

I have a feeling that Cullen and Bloom are having troubles getting anything done worth mentioning. They have a bunch of funding so they are almost expected to come out with the goods. Hopefully they are starting to figure this out. I'm not to optimistic with the whole AAV thing. 

My understanding was that Cullen/Bloom would have some sort of results by the end of summer, as they were actively testing in mice.  It's now winter and we've yet to hear anything.  It could be that something unforeseen came up, an error in the method for example, or something else.  Hard to say.

[Second_chance]

6 hours ago, Evaluate said:

My understanding was that Cullen/Bloom would have some sort of results by the end of summer, as they were actively testing in mice.  It's now winter and we've yet to hear anything.  It could be that something unforeseen came up, an error in the method for example, or something else.  Hard to say.

I understand something unforeseen may have came up but they could at least give up an update. 

[dont quit!17]

10 hours ago, Evaluate said:

My understanding was that Cullen/Bloom would have some sort of results by the end of summer, as they were actively testing in mice.  It's now winter and we've yet to hear anything.  It could be that something unforeseen came up, an error in the method for example, or something else.  Hard to say.

Exactly my thoughts. But I think they are working hard on it and eventually will figure it out. (cautiously optimistic)

[Evaluate]

5 hours ago, Second_chance said:

I understand something unforeseen may have came up but they could at least give up an update. 

I would hope so too, but they don't necessarily owe us anything.  The research is being done with the university and not Editas, so they don't have to be responsive to stock holders.  I think we'll hear when they're ready to update us, even though it's not fun

[hopeful Rylee]

On Monday, January 02, 2017 at 8:52 PM, Evaluate said:

What do you mean?  Who is starting gene editing trials first or gene editing trials for HSV specifically?

Hsv specifically or any. 

[hopeful Rylee]

23 hours ago, ninguno24 said:

Well I was supposing that Editas/Cullen would begin clinical trials for hsv 1 on 2017 but as you can see Cullen says I doubt it as need we need to do more animals test first.

But for sure Excision Therapeutics has a clinical trials for 2018 as you can see in their page http://www.excisionbio.com/pipeline  they are working with Dr Kamel Khalili, like Cullen is working with Editas Medicine.

I guest that they are in a race to get a cure as soon as they can. I don't know if they can advance clinical trials but they are working hard to develop a product that they can sell for cure a disease that many as 90% of people have, just imagine money everywhere for them and that is the principal reason to develop a cure and of course second for health people.

Not mentioned that University of Utrecht led by  Dr. Lebbink  is still working  to find a cure and as you can see their main objective if for herpes simplex virus look official page http://blogs.plos.org/speakingofmedicine/2016/08/04/crispr-puts-up-a-fight-against-persistent-herpesviruses-a-short-animation/

Thanks.

2018 is great news, though  17 would be awesome! Either way, at least there are strides. This is for human trials right?  I wonder his long a clinical trial will have to run... I wish they would update..

[hopeful Rylee]

The study from Dr. Lebbink indicates it wasn't successful at eradicating HSV so far, if I'm reading correctly. 

[Evaluate]

31 minutes ago, hopeful Rylee said:

Hsv specifically or any. 

@ninguno24 posted a bit of a summary above.

At this time, and of course things can and will change, Excision BioTheraputics are forecasting to hit clinical trials (so in people) in 2018 for HSV-1 specifically.  Since the two viruses are very similar, what works with one will very likely work with the other.  Excision is a start up based upon the research out of Temple University.  Successes of Temple's research will likely translate over to Excision.  To be honest I'm still not clear on where Excision is getting their funding from or what all they have secured thus far.  This is a big piece to getting to clinical trials.

Editas has no funding issues I can see, lots of grants and investors, but looks like they're a bit behind where they'd like to be on finishing animal trials before getting into clinical trials for HSV.  Depending on how quickly they finish animal studies, and whether those results are favourable, it could be 2018 as well.

To be honest I think we probably won't see HSV clinical trials until after 2018.  I'm not saying this to be pessimistic, but neither Editas or Excision have shown results in animals yet.  Clinical trails take time to get approval and set up; having reliable/valid results in animal models is the step before going to phase I trials.

Edited January 4, 2017 by Evaluate

[hopeful Rylee]

4 minutes ago, Evaluate said:

@ninguno24 posted a bit of a summary above.

At this time, and of course things can and will change, Excision BioTheraputics are forecasting to hit clinical trials (so in people) in 2018 for HSV specifically.  They don't specify HSV 1/2 but their research has largely been with HSV-1.  Since the two viruses are very similar, what works with one will very likely work with the other.  Excision is a start up based upon the research out of Temple University.  Successes of Temple's research will likely translate over to Excision.  To be honest I'm still not clear on where Excision is getting their funding from or what all they have secured thus far.  This is a big piece to getting to clinical trials.

Editas has no funding issues I can see, lots of grants and investors, but looks like they're a bit behind on finishing animal trials before getting into clinical trials for HSV.  Depending on how quickly they finish animal studies, and whether those results are favourable, it could be 2018 as well.

To be honest I think we probably won't see HSV clinical trials until after 2018.  I'm not saying this to be pessimistic, but neither Editas or Excision have shown results in animals yet.  Clinical trails take time to get approval and set up; having reliable/valid results in animal models is the step before going to phase I trials.

Thanks a lot for explaining and breaking it down. This has me so full if anxiety and depression sometimes I can barely think straight. 

Once in clinical trials, do they run 10 years? I read an article a few months back stating the crispr cure could be out in 5 yrs. I really wish the authors/publishers wouldn't do that. It gives false hope. Hope that one day we will be free again us all some of us have to hang on too. U think it was the one with Dr. Khamil or something like that

Edited January 4, 2017 by hopeful Rylee

[Evaluate]

15 minutes ago, hopeful Rylee said:

Thanks a lot for explaining and breaking it down. This has me so full if anxiety and depression sometimes I can barely think straight. 

Once in clinical trials, do they run 10 years? I read an article a few months back stating the crispr cure could be out in 5 yrs. I really wish the authors/publishers wouldn't do that. It gives false hope. Hope that one day we will be free again us all some of us have to hang on too. 

It's hard to say.  Typical clinical trials run 7-10 years for drugs and vaccines.  There are three considerations though that may change this:

1. Changes to the FDA rules by expediting trials are expected to come into effect.  What effect that will actually have on the timeline I'm not sure.
2. Most vaccines are administered over a period of months (think typically 3 dosages over 6 months) where testing for durability (the effect over six months or one/two years) is extremely important.  Most vaccines take time to measure effectiveness.  You want to make sure the vaccine doesn't wear off and that there are no unintended side effects.  When it comes to CRISPR/Cas and HSV, the effects should be almost instantaneous.  Researchers should know (and especially participants) if it's worked and the extent that it has worked much faster than a vaccine.  This potentially means a faster turn around.
3. Gene editing is new and carries a lot of risk if done improperly, so this could mean more scrutinization.

So, time will tell.  Each organization will also have to individually satisfy the FDA to keep moving ahead with clinical trials.  Depending on how organized they are, the funding they have and the talent they have running/organizing the trials will make a big difference as well.

Keep in mind there are a few vaccines and additional antivirals in the works, so this is not the be all and end all.

Edited January 4, 2017 by Evaluate

[ninguno24]

2 hours ago, hopeful Rylee said:

The study from Dr. Lebbink indicates it wasn't successful at eradicating HSV so far, if I'm reading correctly. 

yeah that's true but he has good new he said that I think the direct applications to treat EBV and HCMV infections may be challenging, as infected cells can travel to many sites in the body and are hence difficult to reach. For HSV-1, HSV-2, or VZV, delivery may be more straight-forward, as here the viruses reside in limited numbers of neurons at defined areas in the human body, such as the trigeminal ganglia.  Also he said that We aim at testing new approaches to also allow targeting of the latent HSV1 genome using the CRISPR/Cas9 system. Additionally, we are working on in vivo model systems to assess the potential therapeutic applications of anti-herpesvirus CRISPRs.

Maybe it was not successful so far, because they got a delivery problem but as soon as they resolve it they will get a cure, as you can  see they were able to erradicate active hsv in 100% so the problem is to reach latent virus and they are working in it.

in other hand do you really think that cure hsv with crispr will take 10 years? 

come on! companies around the world are figting to get a cure not only for hsv but also for diseases that affects a lot of people because this guarantees profitability for them. Remember that these companies have to respond with benefits for their shareholders. 

So I Encouraged you to call them editas or excision and Dr Khalili for getting new info about their project for 2017 and 2018 too to be sure what they are going to do. Im still waiting for their answer because I sent an email to them but only Cullen respond until now.

Thanks!!